NABNEC
22 Dec 2020
NABNEC
ACTRN12616000958482; Ethics 163.17
A randomised phase II study to establish if carboplatin and nab-paclitaxel combination is an effective and tolerable chemotherapy treatment for grade 3 advanced gastrointestinal Neuroendocrine Carcinomas.
Australasian Gastro-Intestinal Trials Group (AGITG)
Cancer Type | Neuroendocrine |
---|---|
Trial Type | Treatment |
Phase | Phase II |
Age Range | 18 years and older |
Sex | Both |
Tumour Stream | - |
Cancer Stage | Locally Recurrent or Locally Advanced |
Anticipated Start Date | 2016-08-19 |
Anticipated End Date | - |
Hospital | Flinders Medical Centre |
---|---|
Clinical Trial Coordinator | Alex Scott-Hoy |
alex.scott-hoy@sa.gov.au | |
Phone | 08 8204 4830 |
Principal Investigator | Professor Chris Karapetis |
Recruitment Status | Recruiting |